BIOCON.NS : Summary for BIOCON INR5 - Yahoo Finance

U.S. Markets closed

Biocon Limited (BIOCON.NS)

NSE - NSE Delayed Price. Currency in INR
Add to watchlist
913.95-11.30 (-1.22%)
At close: 4:59 AM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close925.25
Bid913.95 x
Ask0.00 x
Day's Range911.15 - 938.00
52 Week Range431.00 - 1,020.00
Avg. Volume915,216
Market Cap179.01B
PE Ratio (TTM)16.71
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bloomberg4 days ago

    How One Woman Silenced Her Twitter Trolls With a 78% Stock Rally

    For more than two years Kiran Mazumdar-Shaw had a quarterly date with her Twitter trolls.

  • PR Newswire26 days ago

    Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

    This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers. Mylan and Biocon believe that this has the potential to be the first submission of a proposed biosimilar trastuzumab in the U.S.

  • PR Newswirelast month

    Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency

    HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Nov. 3, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application (MAA) for insulin glargine, a long-acting insulin analog used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. This filing includes analytical, functional and pre-clinical data, as well as results from the pharmacokinetics (PK) and confirmatory efficacy/safety global clinical trial in Type 2 diabetes patients comparing Mylan's and Biocon's Insulin glargine with Lantus.